Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)
Italy flag Italy · Delayed Price · Currency is EUR
1.145
+0.045 (4.09%)
At close: May 19, 2026

BIT:ERFO Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
9.495.835.744.624.84
Other Revenue
0.240.20.190.10.17
9.736.035.934.725.01
Revenue Growth (YoY)
61.32%1.69%25.70%-5.74%24.09%
Cost of Revenue
6.043.493.332.272.24
Gross Profit
3.72.542.62.452.77
Selling, General & Admin
1.821.491.241.040.81
Amortization of Goodwill & Intangibles
0.660.380.370.30.16
Other Operating Expenses
-0.15-0.17-0.22-0.21-0.08
Operating Expenses
2.632.011.761.461.19
Operating Income
1.070.520.840.991.58
Interest Expense
-0.06-0.03-0.03-0.04-0.02
Currency Exchange Gain (Loss)
-0-00--
Other Non Operating Income (Expenses)
0.040.030.0100
EBT Excluding Unusual Items
1.040.530.820.951.57
Gain (Loss) on Sale of Investments
-----0.01
Pretax Income
1.040.530.820.951.56
Income Tax Expense
0.310.170.220.230.39
Net Income
0.740.350.590.721.17
Net Income to Common
0.740.350.590.721.17
Net Income Growth
108.88%-40.23%-17.56%-38.59%2.28%
Shares Outstanding (Basic)
99992
Shares Outstanding (Diluted)
99992
Shares Change (YoY)
-0.68%-0.26%-4.44%500.00%-
EPS (Basic)
0.090.040.070.080.78
EPS (Diluted)
0.090.040.070.080.78
EPS Growth
110.31%-40.08%-13.73%-89.76%-
Free Cash Flow
0.851.170.980.32.1
Free Cash Flow Per Share
0.100.140.110.031.40
Dividend Per Share
--0.060--
Gross Margin
37.97%42.07%43.84%51.91%55.26%
Operating Margin
10.96%8.68%14.11%20.91%31.56%
Profit Margin
7.57%5.85%9.95%15.17%23.29%
Free Cash Flow Margin
8.74%19.46%16.58%6.39%41.87%
EBITDA
1.831.211.561.612.02
EBITDA Margin
18.82%20.09%26.23%34.07%40.40%
D&A For EBITDA
0.770.690.720.620.44
EBIT
1.070.520.840.991.58
EBIT Margin
10.96%8.68%14.11%20.91%31.56%
Effective Tax Rate
29.30%32.96%27.58%24.50%25.06%
Revenue as Reported
10.036.346.265.035.13
Source: S&P Global Market Intelligence. Standard template. Financial Sources.